UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C. 20549
_____________
FORM 8-K
_____________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of
1934
Date of report
(Date of earliest event reported): June 18, 2018
TG Therapeutics, Inc.
(Exact Name of
Registrant as Specified in Charter)
|
Delaware
(State or Other
Jurisdiction
of
Incorporation)
|
001-32639
(Commission File
Number)
|
36-3898269
(IRS Employer
Identification No.)
|
2 Gansevoort Street, 9th
Floor
New York, New York 10014
(Address of
Principal Executive Offices)
(212) 554-4484
(Registrant's
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities
Act.
☐
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act.
☐
Pre-commencement
communications pursuant to Rule 14d-2b under the Exchange
Act.
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange
Act.
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR §240.12b-2). Emerging growth company
☐
If an emerging
growth company, indicate by check mark if the registrant has
elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On June
18, 2018, TG Therapeutics, Inc. (the “Company”) issued
a press release announcing the oral presentation of clinical data
from its ongoing Phase 2 study evaluating umbralisib (TGR-1202),
the Company’s PI3K delta inhibitor, in patients with relapsed
or refractory Chronic Lymphocytic Leukemia (CLL) who are intolerant
to prior BTK or PI3K delta inhibitor therapy, at the 23rd Congress
of European Hematology Association (EHA). On June 18, 2018, the
Company also announced updated results from its Phase 2 multicenter
trial of ublituximab (TG-1101), the Company’s novel
glycoengineered anti-CD20 monoclonal antibody, in relapsing forms
of Multiple Sclerosis (RMS), at the 4th Congress of the European
Academy of Neurology (EAN), in Lisbon, Portugal. Copies of the
press releases are being filed as Exhibits 99.1 and Exhibits 99.2
and incorporated in this Item by reference.
Item 9.01 Financial Statements And
Exhibits.
(d)
Exhibits.
99.1 Press Release, dated June 18,
2018.
99.2 Press Release, dated June 18,
2018.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
TG Therapeutics, Inc.
|
|
|
(Registrant)
|
|
|
|
|
|
|
|
|
|
|
Date: June 18,
2018
|
|
|
|
By: /s/
Sean A.
Power
|
|
|
Sean A.
Power
|
|
|
Chief Financial
Officer
|
|
|
|